340B Program Sales Forecast: 2016-2021

In February 2016, Apexus made available data on total drug sales through the 340B program from 2005 through 2015. These data revealed that, based on total sales, the 340B program more than doubled in size between 2010 and 2015 and expanded by 66 percent between 2013 and 2015 alone. This rate of growth is unprecedented and reflects the cumulative effect of factors that we believe are likely to continue to drive growth for at least the next five years.